Multimodality therapy in stage III non-small cell lung cancer

被引:37
作者
Edelman, MJ
Gandara, DR
Roach, M
Benfield, JR
机构
[1] UNIV CALIF DAVIS,DIV CARDIOTHORAC SURG,MARTINEZ,CA 94553
[2] VET ADM NO CALIF HLTH CARE SYST,MARTINEZ,CA
[3] UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143
关键词
D O I
10.1016/0003-4975(96)00044-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Non-small cell lung cancer commonly presents as locally advanced disease. This category of tumors is heterogeneous. Although some patients clearly benefit from operative management alone, the vast majority (more than 90%) will succumb to their disease within 5 years. In the past decade a large clinical research effort has been undertaken in an attempt to improve on this outcome using a combination of chemotherapy, radiotherapy, and operation. Methods. The English-language literature was reviewed using the headings for lung neoplasms and text words combined modality therapy and multimodality therapy. In addition, the bibliographies of relevant articles were reviewed. Emphasis was placed on prospective randomized trials and large phase II studies. We review the rationale, design, and outcome of these trials, including both operative and nonoperative approaches. Results. Several prospective, randomized trials now demonstrate an advantage to combined modality management over radiotherapy or operation alone when a cisplatin-based chemotherapy regimen is incorporated into the treatment plan. This advantage was seen using both operative and nonoperative approaches. Conclusions. Combined modality therapy offers an improved outcome for patients with stage III non-small cell lung cancer. Whether both operation and radiotherapy are needed for local control, the best sequence of treatment and the optimal chemotherapy regimen remain to be defined.
引用
收藏
页码:1564 / 1572
页数:9
相关论文
共 60 条
[1]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[2]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[3]  
ALBAIN KS, 1993, CHEST, V103, P1
[4]  
ARMSTRONG J, 1992, P AN M AM SOC CLIN, V11, P291
[5]   CLINICAL CHARACTERIZATION OF NON-SMALL-CELL LUNG-CANCER TUMORS SHOWING NEURO-ENDOCRINE DIFFERENTIATION FEATURES [J].
BERENDSEN, HH ;
DELEIJ, L ;
POPPEMA, S ;
POSTMUS, PE ;
BOES, A ;
SLUITER, HJ ;
THE, H .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1614-1620
[6]   PHASE-III TRIAL OF THORACIC IRRADIATION WITH OR WITHOUT CISPLATIN FOR LOCALLY ADVANCED UNRESECTABLE NON-SMALL-CELL LUNG-CANCER - A HOOSIER ONCOLOGY GROUP PROTOCOL [J].
BLANKE, C ;
ANSARI, R ;
MANTRAVADI, R ;
GONIN, R ;
TOKARS, R ;
FISHER, W ;
PENNINGTON, K ;
OCONNOR, T ;
RYNARD, S ;
MILLER, M ;
EINHORN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1425-1429
[7]  
BONOMI P, 1990, CANCER, V66, P2270
[8]  
BONOMI P, 1992, P AN M AM SOC CLIN, V11, P292
[9]  
BURKES R, 1988, LUNG CANCER, V4, pA166
[10]   CISPLATIN CYCLOPHOSPHAMIDE MITOMYCIN COMBINATION CHEMOTHERAPY WITH SUPPORTIVE CARE VERSUS SUPPORTIVE CARE ALONE FOR TREATMENT OF METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
CARTEI, G ;
CARTEI, F ;
CANTONE, A ;
CAUSARANO, D ;
GENCO, G ;
TOBALDIN, A ;
INTERLANDI, G ;
GIRALDI, T .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :794-800